JSPR Jasper Therapeutics, Inc. Common Stock

XNAS 0.51 Delayed
Find condors

Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Fibonacci levels Insider trading

Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.

JSPR $0.51 —
Key stats
$0.51
52-Week Range
$0.32 – $2.52
YTD
-72.53%
Straddle Price
$0.45
P/C Vol Ratio
1.00
Market Cap
$0.0B
Open
$0.51
Day Range
$0.50 – $0.52
Volume
396,739
Prev Close
$0.51
Fair Value

A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.

  • DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
  • Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
  • DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
  • P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
  • Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
  • Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
  • Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
  • Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
10-yr Treasury (rf)4.96%
Beta vs SPY2.00
Cost of Equity (CAPM)15.98% (VRP-adj)
WACC16.10%
Volatility Risk Premium+301.0pp (IV − HV30), ERP adj +50bps
Effective Tax Rate21.0%
Rev. Growth (YoY, DCF input)+3.0%
DCF Horizon5 years explicit + fade
Forward Tilt (NTM/TTM)×1.03 (applied to P/E, EV/EBITDA, P/S)
Free Cash Flow (TTM)$-0.1B
Return on Equity (TTM)-2248.5%
Book / Price33.7% — banking bias active (P/B is primary)
Debt / Equity0.00
Quality Score1/6 — cyclical/struggling (5y DCF)
SMA 50$0.62 (Market Anchor value)
SMA 20 / Bollinger Mid$0.54
Bollinger Width / SMA205885.7% (drives anchor stability)
Net Debt$-0.0B
Market Cap$0B
Blended Fair Value
—
Deviation
—
MethodImplied PriceWeightDetail
DCF n/a 0%
DDM (Gordon) n/a 0%
Peer P/E n/a 0%
Peer EV/EBITDA n/a 0%
Peer P/B n/a 0%
Peer P/S n/a 0%
Market Anchor (SMA50) $0.62 0% stability 0% (BB-width)
Options Expected (B-L 30d) n/a 0%
As of 2026-10-27 · updated
About
Industry (SIC)
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) (2836) · industry map
Exchange
XNAS
Market Cap
$0.0B
Employees
22
List Date
2021-09-27
CIK
0001788028
Next Earnings
2026-11-09 (Pre-Market)
EPS Forecast
($0.06) (3 est.)
Headquarters
Redwood City, CA
Homepage
https://www.jaspertherapeutics.com

Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma…

Summary
—
composite
—
No summary data available for this symbol yet.

Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.

Chart
Seasonality
'21'22'23'24'25'26Avg
Jan---40.95%-37.96%73.08%-71.27%-19.57%-19.33%
Feb---32.43%16.97%74.04%-4.51%-6.12%9.59%
Mar--1.43%-4.74%32.97%-22.94%-35.10%-5.68%
Apr---10.56%-25.70%-15.65%32.61%17.00%-0.46%
May---15.92%18.32%8.21%2.23%-10.89%0.39%
Jun---37.13%-16.97%-9.71%1.83%-21.19%-16.63%
Jul---2.58%8.63%-20.10%-49.48%39.60%-4.79%
Aug---5.00%-19.61%25.72%-2.78%17.33%3.13%
Sep-16.38%-57.91%-39.13%-1.93%-13.77%-16.86%-24.33%
Oct-2.46%-8.77%-9.17%22.43%-5.00%-15.48%*-3.07%
Nov-14.14%-16.69%-10.27%7.24%-12.38%---9.25%
Dec-3.68%-21.35%26.28%-10.81%6.40%---0.63%
Total-32.55%-95.54%-72.39%280.79%-89.05%-53.66%-10.40%
Technical Indicators

Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.

Trend Indicators
  • SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
  • EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
  • MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
  • ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
  • +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
  • RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
  • Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
  • Williams %R — inverted scale: <−80 oversold, >−20 overbought.

Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.

Volume & Volatility
  • Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
  • OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
  • Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
  • ATR / True Range — average daily $ move; sizing and stop-loss reference.
  • HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.

Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →

Trend Indicators

SMA 20: $0.54
SMA 50: $0.62
SMA 200: $0.87
Current: $0.51
EMA 12: $0.52
EMA 26: $0.55
MACD: -0.0346 | Signal: 0.0016
BEARISH
ADX (14): 12.43
RANGE
+DI: 17.86
−DI: 16.90

Momentum Oscillators

RSI (14): 41.03
NEUTRAL
Stoch %K: 32.02
Stoch %D: 29.11
Williams %R: -65.08

Volume & Volatility

BB Upper: $0.62
BB Lower: $0.45
NEUTRAL
OBV: -49,926,364
Vol SMA 20: 380,260
Vol ROC: 18.15%
ATR: $0.05
True Range: $0.03
HV 20: 77.5%
HV 30: 83.1%
HV 60: 86.8%

Data Summary

Data Points: 500
Last Updated:
Date Range: 2024-10-28T00:00:00 – 2026-10-26T00:00:00
AI Analysis

LLM Stock Analysis Report

Executive Summary BULLISH (Confidence Level: 7/10)

Key drivers: Positive updates from Briquilimab studies, potential for deal-making with RobinHood acquisition.

Primary risks: High volatility, negative news sentiment, regulatory issues.

Investment thesis: JSPR is a high-volatility stock with a strong momentum signal. The recent positive update on Briquilimab studies has boosted investor confidence. However, the company's beta and volatility metrics suggest that it may be more susceptible to market fluctuations.

Recent news sentiment impact: Negative headlines from deal-related news have weighed on the stock price. However, the positive update on Briquilimab studies has partially offset this effect.

Technical Analysis Trend Direction: Short-term: Uptrend Medium-term: Uptrend Long-term: Trending sideways

Support/Resistance Levels:

  • Lower band: $0.63 (Bollinger Bands)
  • Middle band: $0.75 (Bollinger Bands)
  • Upper band: $0.87 (Bollinger Bands)

Momentum Signals: RSI interpretation: Neutral (49.68) MACD signal: Bullish (Histogram > 0.01) Bollinger Bands position: Neutral (Price within middle band)

Volume Analysis: Volume trends: Decreasing volume Institutional interest signals: High-volume trading in the options market

News & Sentiment Analysis Recent Headlines Summary: Deal-related news has been negative, with headlines from Benzigna and GlobeNewswire Inc. highlighting potential deal-making and regulatory issues.

Sentiment Assessment: Negative (60% of recent headlines are negative)

Catalyst Identification: Upcoming earnings release could provide a catalyst for the stock price. The recent positive update on Briquilimab studies has created a bullish momentum signal.

Market Narrative: The news sentiment has been negative, but the technical signals suggest a potential uptrend. The market narrative is that JSPR's high volatility and regulatory issues make it a riskier investment opportunity.

Risk & Volatility Assessment Beta Interpretation: High risk (beta > 1.75)

Volatility Regime: Current volatility is higher than historical levels

Options Market Signals: IV rank: 40.6% (Medium) Put/call ratios: Bearish sentiment (3.73) Unusual activity: Options trading volume suggests institutional interest in the options market

Downside Protection: Support level: $0.63 (Bollinger Bands lower band)

Market Context & Positioning Sector Performance: JSPR's sector performance is neutral, with no clear trends emerging.

Institutional Activity: High-volume trading in the options market suggests institutional interest in JSPR's volatility.

Correlation Analysis: JSPR moves relatively independently of the broader market (R-squared interpretation)

Relative Valuation: JSPR is positioned within a trading range, with no clear trend or breakout signal.

Key Levels & Action Items Critical Price Levels:

  • Support: $0.63 (Bollinger Bands lower band)
  • Resistance: $0.87 (Bollinger Bands upper band)

Breakout/Breakdown Levels: Technical levels that could trigger significant moves are the Bollinger Bands' middle and upper bands.

Time-Sensitive Catalysts: Upcoming earnings release could provide a catalyst for the stock price.

Risk Management: Stop-loss levels and position sizing considerations should be based on the options market signals and institutional interest in JSPR's volatility.

Generated
News
All JSPR news →
Earnings History
10 of 10 under expected move
Avg Expected Move
39.41%
Avg Actual Move
3.45%
Each row pairs the pre-earnings straddle-implied expected move with the realized close-to-close move. Sorted oldest first.
Earnings Date Timing Expected Move Actual Move Ratio Outcome
2023-03-08 Pre-Market 4.09% 3.85% 0.94x Within
2023-05-12 Pre-Market 68.63% 5.37% 0.08x Within
2024-03-04 Pre-Market 20.06% 0.91% 0.05x Within
2024-11-07 Pre-Market 12.03% 4.26% 0.35x Within
2025-02-27 Pre-Market 25.00% 2.24% 0.09x Within
2025-05-12 After-Close 7.91% 1.69% 0.21x Within
2025-08-13 Pre-Market 24.56% 4.21% 0.17x Within
2025-11-10 Pre-Market 51.97% 0.00% 0.00x Within
2026-05-14 Pre-Market 67.93% 4.23% 0.06x Within
2026-08-12 Pre-Market 111.97% 7.75% 0.07x Within

Earnings calendar: this week’s reports with expected vs actual moves →

JSPR Options Activity & IV Rank

Volatility Metrics

Current IV: —
7-DTE IV: —
Expected Move: $0.45
7-DTE Move: $0.45
Days to Exp: 25 (2026-11-20)

Options Flow

Call Volume: 2
Put Volume: 2
P/C Volume: 1.0
NEUTRAL
Call OI: 112
Put OI: 0
P/C OI: —
Total OI: 112

ATM Options Pricing

ATM Call: $0.07
ATM Put: $0.38
Call %: 14.8%
Put %: 74.2%

Chain Summary

Chain Volume: 723
Chain OI: 5,988
Last Updated: 10/26/2026
Spread Scanner GPU
Full Algorithm Docs ↗

Each spread is ranked by a composite score built in three stages. Full documentation →

Stage 1 — Base Score (GPU scanner)

score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.

Stage 2 — Skew Adjustment (±25% cap)

RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.

Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
  • RSI <40 bullish / >60 bearish
  • MACD crossover + histogram trend
  • Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
  • Stochastic %K <20 / >80
  • Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
  • Blended ATR + straddle expected-move penalty
  • Bollinger Band signal (+ counter-trend penalty)
  • BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
  • IV rank ≥ 75 → strong boost for credit spreads
  • IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
  • Min open interest across all legs
  • OI < 100 → −0.10 · OI < 500 → −0.05

score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →

Enter a ticker to scan for optimal spread opportunities.

Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.

Dealer Positioning
TYPICAL γ

Estimated net dealer gamma is at the 46th percentile of this name's own daily history, within its typical range. This describes current positioning; it is not a forecast or a trading signal.

Gamma percentile
46%
vs own history
GEX tilt
+0.71
OI-weighted, today
Vanna tilt
+0.47
δ-sensitivity to IV
Charm tilt
-0.58
δ-decay vs time
Vanna tilt +0.47: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.58: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.

Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.

Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.

Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.

This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.

· 4 ATM contracts, 1k total OI
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Metric:
Wing vs ATM
IV(put wing) − IV(ATM), in vol points

How much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.

  • Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
  • Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
  • Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
  • Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each side

Which side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.

  • Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
  • Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
  • Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
  • Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together

Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:

  • High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
  • Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
  • Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d —
— pts EXTREME
as of Oct 26 · No data
30 DTE / 10d —
— pts EXTREME
as of Oct 26 · ATM 443.6% / Wing —

Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.

Volatility Surface

Enter a ticker to render the implied volatility surface.

Volatility Smile

Enter a ticker to render the implied volatility smile.

IV Rank (7 DTE)
IV Rank (30 DTE)
Straddle Price (30 DTE)$0.45Oct 26
Beta Analysis

Risk Metrics

Beta: 1.7843
Alpha: -122.75%
Correlation: 0.2199
R-Squared: 4.8%
Stock Volatility: 103.4%
Market Volatility: 12.7%

Analysis Details

Benchmark: SPY
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own JSPR
2 of 37 tracked investors
InvestorValueShare of their portfolioRankQ/Q sharesSource
Millennium Management Hedge fund
Izzy Englander
$205K
0.00%
#3481 of 3716-69.9%13F
Renaissance Technologies Hedge fund
Jim Simons
$100K
0.00%
#2978 of 3138+34.0%13F

Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions

JSPR Institutional Ownership (13F)

Latest filings — 2026-09-30
Diluted shares outstanding: 19,952,418 (as of 2026-03-31)

Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.

  • Shares — long equity positions in this name, aggregated across share classes.
  • Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
  • % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
  • Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.

Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.

47 filers14,257,331 shares$9.69M value71.46% of float
# Filer Shares Value % of Total % of Float Period
1 Vanguard Group Inc Custodian 1,326,512 $2.43M 25.05% 6.65% 2025-12-31
2 Qiming U.S. Ventures Management, LLC 928,964 $2.21M 22.82% 4.66% 2025-09-30
3 Velan Capital Investment Management LP 2,668,395 $1.12M 11.59% 13.37% 2026-06-30
4 ACORN CAPITAL ADVISORS, LLC 1,438,159 $604.03K 6.23% 7.21% 2026-06-30
5 KINGDON CAPITAL MANAGEMENT, L.L.C. 1,352,106 $569.24K 5.87% 6.78% 2026-06-30
6 Vanguard Capital Management LLC 1,172,021 $493.42K 5.09% 5.87% 2026-06-30
7 Rock Springs Capital Management LP 1,100,726 $463.41K 4.78% 5.52% 2026-06-30
8 Carlyle Group Inc. 1,066,189 $448.87K 4.63% 5.34% 2026-06-30
9 GSA CAPITAL PARTNERS LLP 534,697 $225.00K 2.32% 2.68% 2026-06-30
10 Millennium Management LLC Custodian 486,933 $205.00K 2.12% 2.44% 2026-06-30
11 Lion Point Capital, LP 465,000 $195.76K 2.02% 2.33% 2026-06-30
12 Geode Capital Management, LLC Custodian 263,808 $111.09K 1.15% 1.32% 2026-06-30
13 RENAISSANCE TECHNOLOGIES LLC 237,900 $100.16K 1.03% 1.19% 2026-06-30
14 BlackRock, Inc. Custodian 169,627 $71.41K 0.74% 0.85% 2026-06-30
15 Vanguard Fiduciary Trust Co 149,943 $63.13K 0.65% 0.75% 2026-06-30
16 ADAR1 Capital Management, LLC 140,000 $58.94K 0.61% 0.70% 2026-06-30
17 Quarry LP 131,529 $55.37K 0.57% 0.66% 2026-06-30
18 Jane Street Group, LLC Custodian 101,743 $42.83K 0.44% 0.51% 2026-06-30
19 UBS Group AG Custodian 58,759 $24.74K 0.26% 0.29% 2026-06-30
20 Jain Global LLC 51,185 $21.55K 0.22% 0.26% 2026-06-30
21 OSAIC HOLDINGS, INC. Custodian 45,850 $19.30K 0.20% 0.23% 2026-06-30
22 State Street Corp 44,699 $18.82K 0.19% 0.22% 2026-06-30
23 Northern Trust Corp Custodian 41,882 $17.63K 0.18% 0.21% 2026-06-30
24 DIKER MANAGEMENT LLC 35,000 $15.00K 0.15% 0.18% 2026-06-30
25 Qube Research & Technologies Ltd 33,722 $14.20K 0.15% 0.17% 2026-06-30
2 filers$121.92K notional
# Filer Notional Value % of Total Period
1 Citadel Advisors LLC Custodian $86.73K 71.13% 2026-06-30
2 Jane Street Group, LLC Custodian $35.20K 28.87% 2026-06-30
4 filers$22.47K notional
# Filer Notional Value % of Total Period
1 Citadel Advisors LLC Custodian $9.43K 41.97% 2026-06-30
2 GROUP ONE TRADING LLC Custodian $8.29K 36.91% 2026-06-30
3 Susquehanna International Group, LLP Custodian $4.33K 19.25% 2026-06-30
4 Simplex Trading, LLC Custodian $421 1.87% 2026-06-30

JSPR Insider Trading (Form 4)

Latest: 2026-08-04
Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
Filed Reporter Role Action Shares Avg Price Net $ Link
2026-08-04 Kurt Von Emster Director Grant (A) +7,500 opt — EDGAR
2026-08-04 Thomas G Wiggans Director Grant (A) +7,500 opt — EDGAR
2026-08-04 Judith Anne Shizuru Director Grant (A) +7,500 opt — EDGAR
2026-08-04 Svetlana Lucas Director Grant (A) +7,500 opt — EDGAR
2026-08-04 Patrick J Crutcher Director Grant (A) +7,500 opt — EDGAR
2026-07-22 Matthew E Ros Chief Operating Officer Buy (P) +881 RSU — EDGAR
2026-07-20 Patrick J Crutcher Director Mixed +15,888 opt — EDGAR
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.

JSPR Board & Officers

As of SEC filings through Aug 4, 2026

Directors 7

Officers 4

  • Herb Cross · Chief Financial Officer · since Sep 22, 2023
  • Matthew E Ros · Chief Operating Officer · since Jul 16, 2026
  • Greg Keenan · Chief Medical Officer · since Jul 16, 2026
  • Wenru Song · EVP, Head of R&D · since Jul 16, 2026
Changes in the last 10 years (97)
Jul 16, 2026Wenru Song became EVP, Head of R&D
Jul 16, 2026The company announced the departure of Vishal Kapoor from the board in an SEC filing
Jul 16, 2026The company announced the departure of Scott C. Brun from the board in an SEC filing
Jul 16, 2026Patrick J Crutcher became a director
Jul 16, 2026Matthew E Ros became Chief Operating Officer
Jul 16, 2026Greg Keenan became Chief Medical Officer
May 15, 2026The company announced the departure of Chris Nolet from the board in an SEC filing
Feb 10, 2026Jeetinder Singh Mahal first listed as a director in an SEC filing
Jan 2, 2026The company announced the departure of Ron Martell as President and CEO in an SEC filing
Jul 8, 2025The company announced the departure of Edwin Jonathan Tucker as Chief Medical Officer in an SEC filing
Jun 6, 2025Ron Martell listed as President and CEO (previously President, CEO and Director) in SEC filings
Jun 18, 2024Svetlana Lucas became a director
Jun 17, 2024The company announced the departure of Anna Louise French from the board in an SEC filing
Feb 12, 2024TC Group, LLC reported in an SEC filing no longer being a 10% owner
Feb 12, 2024Carlyle Investment Management LLC reported in an SEC filing no longer being a 10% owner
Feb 12, 2024Carlyle Holdings I L.P. reported in an SEC filing no longer being a 10% owner
Feb 12, 2024Carlyle Holdings I GP Sub L.L.C. reported in an SEC filing no longer being a 10% owner
Feb 12, 2024Carlyle Holdings I GP Inc. reported in an SEC filing no longer being a 10% owner
Feb 12, 2024Carlyle Group Inc. reported in an SEC filing no longer being a 10% owner
Feb 12, 2024Carlyle Genesis UK LLC reported in an SEC filing no longer being a 10% owner
Not reported recently (6)
  • Roche Finance Ltd · Last reported as a 10% owner in an SEC filing dated Jan 26, 2023
  • Roche Holding Ltd · Last reported as a 10% owner in an SEC filing dated Jan 26, 2023
  • Peter R Dolan · Last reported as a director in an SEC filing dated Nov 19, 2019
  • Ernest Mario · Last reported as a director in an SEC filing dated Nov 19, 2019
  • Glenn Reicin · Last reported as a director in an SEC filing dated Nov 19, 2019
  • Fredric N Eshelman · Last reported as a director in an SEC filing dated Nov 19, 2019
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.

JSPR Proposed Insider Sales (Form 144)

Latest: 2024-12-12
Last 30d: 0 filings  ·  Last 90d: 0 filings

What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.

How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.

10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.

"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.

Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.

Filed Filer Role Shares Notice Value Planned Sale Broker Plan Link
2024-12-12 Jeetinder Singh Mahal Executive Officer 900 $20.2K 2024-12-12 Raymond James & Associates, Inc. 10b5-1 EDGAR
2024-09-12 Jeetinder Singh Mahal Executive Officer 900 $18.6K 2024-09-12 Raymond James & Associates, Inc. 10b5-1 EDGAR
2024-06-12 Jeetinder Singh Mahal Executive Officer 900 $21.6K 2024-06-12 Raymond James & Associates, Inc. 10b5-1 EDGAR
2024-03-12 Jeetinder Singh Mahal Executive Officer 900 $23.9K 2024-03-12 Raymond James & Associates, Inc. 10b5-1 EDGAR
2024-03-06 Lis William Director 16,000 $336.5K 2024-03-06 Morgan Stanley Smith Barney LLC … — EDGAR
2023-10-13 William Lis Director 7,965 $6.8K 2023-10-13 Raymond James & Associates, Inc. 10b5-1 EDGAR
2023-06-13 Jeetinder Singh Mahal Executive Officer 9,000 — 2023-06-13 Raymond James & Associates, Inc. 10b5-1 EDGAR
2023-04-14 French Anna Louise Director 7,000 $10.4K 2023-04-14 ETRADE FINANCIAL CORPORATION — EDGAR
2023-04-13 Lis William Director 8,500 $12.2K 2023-04-13 ETRADE FINANCIAL CORPORATION — EDGAR
2023-04-13 EMSTER KURT VON Officer 9,075 $13.5K 2023-04-13 ETRADE FINANCIAL CORPORATION — EDGAR
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
ETF Holders
2 ETFs hold JSPR
2 shown · $664.35K total exposure
# ETF Provider Weight $ Exposure ETF AUM As Of
1 VTI Vanguard Morningstar Total Stock Market ETF Vanguard 0.00% $483,367 — 2026-09-30
2 VXF Vanguard Extended Market ETF Vanguard 0.00% $180,979 — 2026-09-30
Fundamentals

Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.

Metrics
  • Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
  • Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
  • Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
  • Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
  • Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
  • YoY growth — compare to the same quarter a year earlier to remove seasonality.
  • Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
  • Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.

TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.

Trailing P/E
—
TTM Diluted EPS
$-2.68
TTM Revenue
—
TTM Net Income
$-55.73M
TTM Op. Cash Flow
$-68.87M
Quarterly figures (12 quarters)
QuarterPeriod EndRevenueNet IncomeDiluted EPSOp. Cash Flow
Q1 '262026-03-31—$-1.17M$-0.04$-14.55M
Q4 '252025-12-31—$-9.10M$0.23$-21.87M
Q3 '252025-09-30—$-18.74M$-1.13$-17.00M
Q2 '252025-06-30—$-26.72M$-1.74$-15.45M
Q1 '252025-03-31—$-21.24M$-1.41$-22.84M
Q4 '242024-12-31—$-24.32M$-1.64$-21.13M
Q3 '242024-09-30—$-18.64M$-1.24$-14.05M
Q2 '242024-06-30—$-14.58M$-0.97$-11.68M
Q1 '242024-03-31—$-13.73M$-1.03$-15.74M
Q4 '232023-12-31—$-16.58M$-1.50$-16.48M
Q3 '232023-09-30—$-17.54M$-1.60$-11.98M
Q2 '232023-06-30—$-16.08M$-1.47$-13.27M
Q1 2026 • period ending 2026-03-31 • filed 2026-05-14
Valuation

Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.

Price Multiples
  • P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
  • P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
  • P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
  • EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
  • EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
  • ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
  • ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
  • Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
  • FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
  • Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
  • Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
  • Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
  • Multiples expanding while earnings are flat = sentiment-driven rally.
  • Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
2.97
P/S
—
EV/EBITDA
—
EV/Sales
—
ROE
-1639.2%
ROA
-263.1%
Div Yield
0.00%
FCF Yield
-682.94%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$10.08M
as of 2026-10-26
Short Interest & Float

Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.

Metric definitions
  • Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
  • SI % of Float — short interest / free float. The key crowding metric.
  • Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
  • Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
  • Free Float — shares available for public trading (total shares minus insider / restricted).
  • Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
  • SI % of Float < 5% — typical, no particular signal.
  • 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
  • 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
  • >30% — extreme; borrow is likely expensive and squeeze risk is material.
  • Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
  • Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
  • A sudden drop in SI after a rally may indicate a squeeze in progress.

Short interest is reported mid-month and end-of-month; short volume is daily.

Short Interest
6.22M
SI % of Float
21.73%
Days to Cover
16.30
Short Vol Ratio
86.6%
Free Float
28.62M
Float %
86.0%
Short interest 2026-09-30 • Short volume 2026-10-26 • Float 2026-08-14